BACKGROUND: Whether ampullary neoplasms are best surgically managed by pancreaticoduodenectomy versus local ampullectomy is controversial. We sought to examine the outcome of patients undergoing pancreaticoduodenectomy versus ampullectomy, as well as to identify factors predictive of lymph node metastasis in patients with ampullary neoplasms. METHODS: Between 1970 and 2007, 450 patients who underwent surgical resection of ampullary adenoma or adenocarcinoma were identified from a prospective, single-institution database. Data on clinicopathologic factors, morbidity, mortality, and survival were analyzed. RESULTS: The initial surgical procedure was pancreaticoduodenectomy in 96.7% patients and ampullectomy in 3.3%. Final diagnosis was invasive adenocarcinoma (77.1%) or adenoma (22.9%). Median tumor size was similar for adenomas associated with an adenocarcinoma (2.5 cm) versus adenomas without invasive cancer (2.9 cm; P=0.71). Morbidity was comparable with pancreaticoduodenectomy (52.2%) versus ampullectomy (33.3%; P=0.15), as was 30-day mortality (pancreaticoduodenectomy, 2.1% versus ampullectomy, 0%; P=0.6). Metastatic disease to regional lymph nodes was present in 54.5% patients with adenocarcinoma. Factors associated with presence of lymph node metastasis included tumor size > or = 1 cm (OR 2.1), poor histologicgrade (OR 4.8), perineural invasion (OR 3.0), microscopic vessel invasion (OR 6.6), and depth of invasion > pT1 (OR 4.3; all P<0.05). Specifically, risk of lymph node metastasis increased with T stage (T1, 28.0%; T2, 50.9%; T3, 71.7%; T4, 77.3%; P<0.001). CONCLUSION: When surgery is indicated, radical resection is required for early invasive adenocarcinoma of the ampulla of Vater, as lymph node metastases are present in nearly 30% of patients with T1 disease. Pancreaticoduodenectomy should be the preferred approach for most ampullary neoplasms that require surgical resection.
BACKGROUND: Whether ampullary neoplasms are best surgically managed by pancreaticoduodenectomy versus local ampullectomy is controversial. We sought to examine the outcome of patients undergoing pancreaticoduodenectomy versus ampullectomy, as well as to identify factors predictive of lymph node metastasis in patients with ampullary neoplasms. METHODS: Between 1970 and 2007, 450 patients who underwent surgical resection of ampullary adenoma or adenocarcinoma were identified from a prospective, single-institution database. Data on clinicopathologic factors, morbidity, mortality, and survival were analyzed. RESULTS: The initial surgical procedure was pancreaticoduodenectomy in 96.7% patients and ampullectomy in 3.3%. Final diagnosis was invasive adenocarcinoma (77.1%) or adenoma (22.9%). Median tumor size was similar for adenomas associated with an adenocarcinoma (2.5 cm) versus adenomas without invasive cancer (2.9 cm; P=0.71). Morbidity was comparable with pancreaticoduodenectomy (52.2%) versus ampullectomy (33.3%; P=0.15), as was 30-day mortality (pancreaticoduodenectomy, 2.1% versus ampullectomy, 0%; P=0.6). Metastatic disease to regional lymph nodes was present in 54.5% patients with adenocarcinoma. Factors associated with presence of lymph node metastasis included tumor size > or = 1 cm (OR 2.1), poor histologicgrade (OR 4.8), perineural invasion (OR 3.0), microscopic vessel invasion (OR 6.6), and depth of invasion > pT1 (OR 4.3; all P<0.05). Specifically, risk of lymph node metastasis increased with T stage (T1, 28.0%; T2, 50.9%; T3, 71.7%; T4, 77.3%; P<0.001). CONCLUSION: When surgery is indicated, radical resection is required for early invasive adenocarcinoma of the ampulla of Vater, as lymph node metastases are present in nearly 30% of patients with T1 disease. Pancreaticoduodenectomy should be the preferred approach for most ampullary neoplasms that require surgical resection.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; David C Chang; Taylor S Riall; Richard D Schulick; Michael A Choti; JoAnn Coleman; Mary B Hodgin; Patricia K Sauter; Christopher J Sonnenday; Christopher L Wolfgang; Michael R Marohn; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: M A Talamini; R C Moesinger; H A Pitt; T A Sohn; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1997-05 Impact factor: 12.969
Authors: P Katsinelos; G Paroutoglou; J Kountouras; A Beltsis; B Papaziogas; K Mimidis; C Zavos; S Dimiropoulos Journal: Surg Endosc Date: 2006-02-27 Impact factor: 4.584
Authors: E E Lagoudianakis; D Tsekouras; N Koronakis; J Chrysicos; F Archontovasilis; K Filis; V Katergiannakis; A Manouras Journal: J BUON Date: 2008 Oct-Dec Impact factor: 2.533
Authors: Taylor S Riall; John L Cameron; Keith D Lillemoe; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Daniel Laheru; Ralph H Hruban; Charles J Yeo Journal: J Gastrointest Surg Date: 2005-12 Impact factor: 3.267
Authors: George A Poultsides; Lyen C Huang; John L Cameron; Richard Tuli; Leslie Lan; Ralph H Hruban; Timothy M Pawlik; Joseph M Herman; Barish H Edil; Nita Ahuja; Michael A Choti; Christopher L Wolfgang; Richard D Schulick Journal: Ann Surg Oncol Date: 2011-12-14 Impact factor: 5.344
Authors: F Francesco di Mola; Francesca Tavano; R Rita Rago; Antonio De Bonis; M Rosa Valvano; Angelo Andriulli; Pierluigi di Sebastiano Journal: Langenbecks Arch Surg Date: 2014-03-29 Impact factor: 3.445
Authors: Stephanie Downs-Canner; Wald J Van der Vliet; Stijn J J Thoolen; Brian A Boone; Amer H Zureikat; Melissa E Hogg; David L Bartlett; Mark P Callery; Tara S Kent; Herbert J Zeh; A James Moser Journal: J Gastrointest Surg Date: 2014-10-28 Impact factor: 3.452
Authors: Ibrahim Nassour; Alana Christie; Michael A Choti; John C Mansour; Rebecca M Minter; Patricio M Polanco; Mathew M Augustine; Matthew R Porembka; Xian-Jin Xie; Sam C Wang Journal: J Gastrointest Surg Date: 2018-03-15 Impact factor: 3.452
Authors: Wiriyaporn Ridtitid; Damien Tan; Suzette E Schmidt; Evan L Fogel; Lee McHenry; James L Watkins; Glen A Lehman; Stuart Sherman; Gregory A Coté Journal: Gastrointest Endosc Date: 2013-10-01 Impact factor: 9.427